Abstract 475: Cationic Peptides in Inflammation and Atherosclerosis
Background Apoprotein (Apo A1) and apoprotein E mimetic peptides are known to reduce atherosclerosis. Antioxidant, anti-inflammatory, and hypolipidemic properties have been suggested to contribute to the anti-atherosclerotic effects. In this study, we tested whether three distinct and unrelated cationic peptides would inhibit inflammatory response to lipopolysaccharide (LPS) and oxidized low density lipoprotein (Ox-LDL).
Methods 5F-mimetic peptide of apoA1, LL27 derived from the anti-microbial peptide CAMP, and a human glycodelin derived peptide were commercially synthesized. RAW 264.7 cells were incubated with LPS or Ox-LDL, pretreated with and without peptides. RNA was isolated from treated cells and real time PCR was performed using mouse IL-1α and IL-6 primers.
Results Increased IL-1α and IL-6 gene expression was observed in the presence of LPS/Ox-LDL. However, peptides showed dual effect as they induced inflammatory markers in the presence of LPS except for LL27 but all peptides inhibited the Ox-LDL-induced inflammatory gene expressions. The results suggest that these peptides may have dual effects on inflammatory cytokine genes in the presence of LPS and Ox-LDL.
Conclusion Based on these results, we predict that lysine-rich cationic peptides could have therapeutic potential in reducing CVD/atherosclerosis-associated inflammation. However, specific receptors, presence of lipids, and other factors may influence their effects.
- © 2013 by American Heart Association, Inc.